The trial, sponsored by Shanghai Cell Therapy Group Co., Ltd, investigates the use of αPD1-MSLN-CAR T cells in patients with MSLN-positive advanced solid tumors, including ovarian cancer, cholangiocarcinoma, and colorectal cancer. Given the increasing prevalence of solid tumors and the limitations of current therapies, this innovative approach could address significant unmet medical needs. The competitive landscape includes other CAR T cell therapies targeting solid tumors, but the unique mechanism of PD-1 nanobody secretion may provide a differentiated therapeutic profile. Successful outcomes could position the sponsor favorably in the CAR T market, which is projected to grow significantly, particularly in oncology. Diligence should focus on regulatory pathways, potential partnerships for commercialization, and the evolving landscape of CAR T therapies.